SignalCorporate
Iovance Biotherapeutics GAAP EPS of -$0.05 beats by $0.04, revenue of $121.47M beats by $5.9M
Iovance beat EPS and revenue estimates, driven by $121.47M revenue exceeding by $5.9M.
What changed
Iovance beat EPS and revenue estimates, driven by $121.47M revenue exceeding by $5.9M.
Why it matters
Iovance beat EPS and revenue estimates, driven by $121.47M revenue exceeding by $5.9M. — impact context not separately stored; see What changed.